Chronic kidney disease market to grow at 19.6 percent CAGR in seven major markets during 2023-33: GlobalData – Healthcare News


GlobalData, a data and analytics company, on Wednesday predicted that the chronic kidney disease (CKD) market will grow at a compound annual growth rate (CAGR) of 19.6 percent from $2.2 billion in 2023 to $13.5 billion in 2033 across the seven major markets (7MM).

According to the analytics company, pipeline approvals of varying mechanisms of action and an influx of newly diagnosed patients are some fo the driving factors of this market.

GlobalData’s latest report “Chronic Kidney Disease: Seven-Market Drug Forecast and Market Analysis,” reveals that the US will contribute the most to the growth of the CKD market due to the higher prevalence of CKD in this market, as well as the substantially higher cost of prescription medications in the country compared with Europe and Japan.

Wockhardt claims breakthrough in cancer treatment with experimental drug Zaynich

Wockhardt claims breakthrough in drug-resistant infection in cancer patients with experimental drug Zaynich; US body awards highest susceptibility to the antibiotic

Dr Reddy

Dr. Reddy’s to acquire Haleon’s global portfolio of consumer healthcare brands in Nicotine Replacement Therapy

API, API market, API manufacturing market, API market of India, Supriya Lifescience, health news, pharma news,

Our primary goal is to double our revenue, enter higher-margin niche segments and increase footprint: Dr. Saloni Wagh, Director, Supriya Lifescience Ltd.

Antimicrobial Resistance, AMR, AMR in India, healthcare news,

We are working on reviving its R&D strengths; To launch new products 1-2 months: Rajnish Rohatgi, CEO, Orchid Pharma

“The pressure on pharmaceutical companies to be more innovative with their therapies and tackle unmet needs is increasing. Companies are approaching the CKD market with the strategies of optimizing treatment safety and compliance, as well as developing novel drug classes. The use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers has remained relatively consistent, and the use of sodium-glucose transporter 2 inhibitors has become well established for CKD,” Kajal Jaddoo, Senior Pharma Analyst at GlobalData said.

Over the forecast period of 2023–33, GlobalData expects the launches of promising pipeline drugs REACT (rilparencel), Ozempic (semaglutide), zibotentan + dapagliflozin combination, and balcinrenone + dapagliflozin combination to increase market size and further promote growth.

“It will be easier for new drug entrants to capture CKD market share if they offer a novel mechanism of action or help to improve compliance. The key opinion leaders interviewed by GlobalData hold mixed views on adding another drug on top of their patients’ complex treatment regimens. Overall, nephrologists surveyed by GlobalData have indicated that the pipeline for CKD is somewhat promising, but a significant improvement in efficacy would have to be demonstrated by any therapy for it to become either a replacement or add-on to the existing therapies,” Jaddoo said.


Leave a Reply

Your email address will not be published. Required fields are marked *